Mkts

enGene Therapeutics Inc.

NASDAQ: ENGN
$1.60+0.04 (+2.56%)
As of Oct 26, 1:20 PM ET

Key statistics

Day range
1.551.63
52-week range
1.4012.25
Today
Open1.56
Previous close1.60
Volume730.2K
Valuation
Market cap104.55M
P/E ratio—
EPS (TTM)-2.08
Income & risk
Dividend / yield—
Beta-0.28
Avg volume841.3K
Discussion

ENGN News

Stories mentioning ENGN from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ2 '26Apr 30Q1 '26Jan 31Q4 '25Oct 31Q3 '25Jul 31Q2 '25Apr 30Q1 '25Jan 31Q4 '24Oct 31Q3 '24Jul 31
Income Statement
Revenue
Cost of Goods Sold
Gross Profit0.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development22,19522,25531,72222,57520,20919,97411,27311,549
Sales General & Admin
Total Operating Expenses31,96831,18539,48129,94727,12426,61317,45516,759
Operating Income (Loss)(31,968)(31,185)(39,481)(29,947)(27,124)(26,613)(17,455)(16,759)
Interest Income2,6632,7401,9752,2332,4882,7303,0243,380
Interest Expense
Other Expense(177.00)(87.00)(121.00)(280.00)(205.00)37.00(93.00)(47.00)
Pretax Income(30,227)(29,752)(38,377)(28,752)(25,575)(24,598)(15,280)(14,177)
Tax Provision0.000.00(497.00)239.00240.0018.0019.00(29.00)
Net Income (Loss)(30,227)(29,752)(37,880)(28,991)(25,815)(24,616)(15,299)(14,148)
Earnings Per Share (Basic)(0.43)0.44(0.74)0.57(0.51)0.48(0.40)0.32
Earnings Per Share (Diluted)(0.43)0.44(0.74)0.57(0.51)0.48(0.40)0.32
Weighted Average Shares Outstanding (Basic)69,72567,26351,11951,09851,01950,97737,78244,169
Weighted Average Shares Outstanding (Diluted)69,72567,26351,11951,09851,01950,97737,78244,169

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About ENGN

enGene Therapeutics Inc. (NASDAQ: ENGN) is a stock listed on the Nasdaq Stock Market under the ticker symbol ENGN. It last traded at $1.60 (Oct 26, 2026, 1:20 PM ET), up 2.6% on the day. That gives enGene Therapeutics a market capitalisation of $104.5M.

Over the past 52 weeks ENGN has traded between $1.40 and $12.25.

For the quarter ended Apr 30, 2026 it reported a net loss of $30.2M.

Last 4 quarters
Quarter endedRevenueNet income
Apr 30, 2026—-$30.2M
Jan 31, 2026—-$29.8M
Oct 31, 2025—-$37.9M
Jul 31, 2025—-$29.0M

From enGene Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…